Map Home
Type / to search with text or keywords
/
keyboard shortcut: Type "/" on your keyboard for a quick search
Search button
Loading...
Loading...
Scroll left
Grants
Citations
H-Index
Patents
News
Books
Scroll right
Collapse sidebar
Data issues & feedback
Adjust height of sidebar
KMap
Grant
Adjust height of sidebar
KMap
Grant
Actuate 1801. Phase 1/2 Study of 9-ING-41, a Glycogen Synthase Kinase-3 Beta (GSK-3B) Inhibitor, as a Single Agent and Combined with Chemotherapy, in Patients with Refractory Hematologic Malignancies
Sponsored by Actuate Therapeutics, Inc.
Active
$432.5K Funding
6 People
External
Related Topics
gsk-3b inhibitor,
hematologic malignancies,
chemotherapy
People
Brianna Denton
(CD)
Cancer Center Division
﹒Research Compliance Manager I
Diana Dawson
(CD)
Cancer Center Division
﹒Research Compliance Administrator II
Hina Arif Tiwari
Co-Investigator (COI)
Pathology and Lab Medicine
﹒Professor
Brianna Loughran
(CD)
Cancer Center Division
﹒Clinical Research Coordinator II
Rachna Shroff
Principal Investigator (PI)
Medicine
﹒Professor
Bryan Clines
(CD)
Cancer Center Division
﹒Research Compliance Administrator III
